Development of Lipid-Engineered PSMA-Targeted Radioligands with Quinoline Scaffold

Nine 68Ga-labeled PSMA-targeted radioligands were evaluated in a PC-3 PIP xenograft mouse model using PET imaging. The dataset, authored by Tao Zhang and last updated in April 2026, contains results from a proof-of-concept study validating lipid and fatty acid conjugation strategies. Cellular studies and molecular docking simulations confirmed PSMA specificity and protein-binding properties for the synthesized ligands.

Use Cases

• Compare tumor uptake and retention of different radioligand designs based on PET imaging data.
• Validate molecular docking simulations against experimental cellular binding studies.
• Assess the impact of lipidation and fatty acid modification strategies on tumor-to-nontarget (T/NT) ratios.
• Evaluate kidney retention levels for potential therapeutic radioligands like [177Lu]Lu-PDA2-C6.

Strengths

• Includes data from nine distinct 68Ga-labeled PSMA-targeted radioligands.
• Validation involves multiple methods: PET imaging, biodistribution studies, cellular assays, and molecular docking.
• Specific compounds ([68Ga]Ga-PDA2-C6, [68Ga]Ga-PDA1-1) are identified as having pronounced tumor retention.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The 1.1 MB file size suggests a relatively small dataset.

Provenance

Source

figshare

Collection Method

Data likely originates from a laboratory study involving ligand synthesis, radiolabeling, in vitro cellular assays, in vivo PET imaging in a mouse xenograft model, and computational molecular docking.

Freshness

Last updated 2026-04-22 11:36:11; freshness should be verified.